These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 8104682)

  • 21. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Yang CH; Huang CJ; Yang CS; Chu YC; Cheng AL; Whang-Peng J; Yang PC
    Cancer Res; 2005 Aug; 65(15):6943-9. PubMed ID: 16061679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status.
    Borbé R; Rieger J; Weller M
    Cancer Chemother Pharmacol; 1999; 44(3):217-27. PubMed ID: 10453723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines.
    Perez EA; Buckwalter CA
    Cancer Chemother Pharmacol; 1998; 41(6):448-52. PubMed ID: 9554587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.
    Zeng S; Chen YZ; Fu L; Johnson KR; Fan W
    Clin Cancer Res; 2000 Sep; 6(9):3766-73. PubMed ID: 10999771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
    Sledge GW; Robert N; Sparano JA; Cobeligh M; Goldstein LJ; Neuberg D; Rowinsky E; Baughman C; McCaskill-Stevens W
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):15-8. PubMed ID: 7939756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Ando J; Matsui J; Suzuki K; Ikeda T; Inoue Y; Adachi K
    Br J Cancer; 1996 Sep; 74(5):704-10. PubMed ID: 8795571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin 6 differentially potentiates the antitumor effects of taxol and vinblastine in U266 human myeloma cells.
    Aoyama M; MacIsaac D; Bukowski RM; Ganapathi MK
    Clin Cancer Res; 1998 Apr; 4(4):1039-45. PubMed ID: 9563900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Chou TC; Motzer RJ; Tong Y; Bosl GJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of GL331 in combination with paclitaxel: GL331's interference with paclitaxel-induced cell cycle perturbation and apoptosis.
    Huang TS; Shu CH; Chao Y; Chen LT
    Anticancer Drugs; 2001 Mar; 12(3):259-66. PubMed ID: 11290873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of paclitaxel (Taxol) and irradiation. In-vitro differences between tumor and fibroblastic cells.
    Cordes N; Plasswilm L; Sauer R
    Strahlenther Onkol; 1999 Apr; 175(4):175-81. PubMed ID: 10230460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay.
    Koechli OR; Sevin BU; Perras JP; Chou TC; Angioli R; Steren A; Untch M; Averette HE
    Breast Cancer Res Treat; 1993 Oct; 28(1):21-7. PubMed ID: 7907234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer.
    Waltmire CN; Alberts DS; Dorr RT
    Anticancer Drugs; 2001 Aug; 12(7):595-602. PubMed ID: 11487716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Ando J; Tsunoda S
    Breast Cancer Res Treat; 1999 Jul; 56(1):79-90. PubMed ID: 10517345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection of p53 wild type cells from taxol by genistein in the combined treatment of lung cancer.
    Tokalov SV; Abramyuk AM; Abolmaali ND
    Nutr Cancer; 2010; 62(6):795-801. PubMed ID: 20661829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
    Fujimoto S; Chikazawa H
    Jpn J Cancer Res; 1998 Dec; 89(12):1343-51. PubMed ID: 10081496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.
    Bertrand R; O'Connor PM; Kerrigan D; Pommier Y
    Eur J Cancer; 1992; 28A(4-5):743-8. PubMed ID: 1326304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cycloheximide inhibits the cytotoxicity of paclitaxel (Taxol).
    Liebmann J; Cook JA; Teague D; Fisher J; Mitchell JB
    Anticancer Drugs; 1994 Jun; 5(3):287-92. PubMed ID: 7919452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.